Tweet
Angew Chem Int Ed Engl. 2017 Apr 26. doi: 10.1002/anie.201702005. [Epub ahead of print]
Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition.
Lauster D1, Glanz M2,3, Bardua M4, Ludwig K5, Hellmund M6, Hoffmann U4, Hamann A4, B?ttcher C5, Haag R6, Hackenberger CPR2,3, Herrmann A1.
Author information
Abstract
To inhibit binding of the influenza A virus to the host cell glycocalyx, we generate multivalent peptide-polymer nanoparticles binding with nanomolar affinity to the virus via its spike protein hemagglutinin. The chosen dendritic polyglycerol scaffolds are highly biocompatible and well suited for a multivalent presentation. We could demonstrate in vitro that by increasing the size of the polymer scaffold and adjusting the peptide density, viral infection is drastically reduced. Such a peptide-polymer conjugate qualified also in an in vivo infection scenario. With this study we introduce the first non-carbohydrate-based, covalently linked, multivalent virus inhibitor in the nano- to picomolar range by ensuring low peptide-ligand density on a larger dendritic scaffold.
? 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
KEYWORDS:
antiviral agents; in vivo studies; influenza virus; multivalency; peptides
PMID: 28444849 DOI: 10.1002/anie.201702005
Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition.
Lauster D1, Glanz M2,3, Bardua M4, Ludwig K5, Hellmund M6, Hoffmann U4, Hamann A4, B?ttcher C5, Haag R6, Hackenberger CPR2,3, Herrmann A1.
Author information
Abstract
To inhibit binding of the influenza A virus to the host cell glycocalyx, we generate multivalent peptide-polymer nanoparticles binding with nanomolar affinity to the virus via its spike protein hemagglutinin. The chosen dendritic polyglycerol scaffolds are highly biocompatible and well suited for a multivalent presentation. We could demonstrate in vitro that by increasing the size of the polymer scaffold and adjusting the peptide density, viral infection is drastically reduced. Such a peptide-polymer conjugate qualified also in an in vivo infection scenario. With this study we introduce the first non-carbohydrate-based, covalently linked, multivalent virus inhibitor in the nano- to picomolar range by ensuring low peptide-ligand density on a larger dendritic scaffold.
? 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
KEYWORDS:
antiviral agents; in vivo studies; influenza virus; multivalency; peptides
PMID: 28444849 DOI: 10.1002/anie.201702005